Clinical Study on the Relationship between Gene Mutation Profile and Prognosis in Pediatric Acute Lymphocyte Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.01.003
- Author:
Yan CHEN
1
;
Shan-Shan QI
2
;
Li-Li DING
2
;
Yu DU
2
;
Na SONG
2
;
Zhuo WANG
2
;
Li YANG
2
;
Ming SUN
2
;
Hao XIONG
3
Author Information
1. Laboratory of Pediatric Hematology， Wuhan Children's Hospital， Tongji Medical College， Huazhong University of Science ＆ Technology, Wuhan 430016， Hubei Province， China.
2. Department of Hematology and Oncology， Wuhan Children's Hospital， Tongji Medical College， Huazhong University of Science ＆ Technology, Wuhan 430016， Hubei Province， China.
3. Department of Hematology and Oncology， Wuhan Children's Hospital， Tongji Medical College， Huazhong University of Science ＆ Technology, Wuhan 430016， Hubei Province， China,E-mail: 22587481@qq.com.
- Publication Type:Journal Article
- Keywords:
acute lymphoblastic leukemia;
genetic variants;
next-generation sequencing;
prognosis
- MeSH:
Child;
Humans;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Cell Cycle Proteins/genetics*;
Proto-Oncogene Proteins p21(ras)/genetics*;
Retrospective Studies;
Ubiquitin-Protein Ligases/genetics*;
Prognosis;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma;
Mutation;
Lymphocytes
- From:
Journal of Experimental Hematology
2023;31(1):17-24
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the gene mutation profile in children with acute lymphocyte leukemia (ALL) and to explore its prognostic significance.
METHODS:Clinical data of 249 primary pediatric ALL patients diagnosed and treated in the Department of Hematological Oncology of Wuhan Children's Hospital from January 2018 to December 2021 were analyzed retrospectively. Next-generation sequencing (NGS) was used to obtain gene mutation data and analyze the correlation between it and the prognosis of children with ALL.
RESULTS:227 (91.2%) were B-ALL, 22 (8.8%) were T-ALL among the 249 cases, and 178 (71.5%) were found to have gene mutations, of which 85 (34.1%) had ≥3 gene mutations. NRAS(23.7%), KRAS (22.9%),FLT3(11.2%), PTPN11(8.8%), CREBBP (7.2%), NOTCH1(6.4%) were the most frequently mutated genes, the mutations of KRAS, FLT3, PTPN11, CREBBP were mainly found in B-ALL, the mutations of NOTCH1 and FBXW7 were mainly found in T-ALL. The gene mutation incidence of T-ALL was significantly higher than that of B-ALL (χ2= 5.573，P＜0.05) and were more likely to have co-mutations (P＜0.05). The predicted 4-year EFS rate (47.9% vs 88.5%, P＜0.001) and OS rate (53.8% vs 94.1%, P＜0.001) in children with tp53 mutations were significantly lower than those of patients without tp53 mutations. Patients with NOTCH1 mutations had higher initial white blood cell count （128.64×109/L vs 8.23×109/L，P＜0.001）, and children with NOTCH1 mutations had a lower 4-year EFS rate than those of without mutations (71.5% vs 87.2%, P＝0.037).
CONCLUSION:Genetic mutations are prevalent in childhood ALL and mutations in tp53 and NOTCH1 are strong predictors of adverse outcomes in childhood ALL, with NGS contributing to the discovery of genetic mutations and timely adjustment of treatment regimens.
